Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

fludarabine phosphate 90Cyclophosphamide 85Mycophenolic Acid 67Peripheral Blood Stem Cell Transplantation 65Whole-Body Irradiation 59Tacrolimus 58Cyclosporine 46Busulfan 45Antilymphocyte Serum 39fludarabine 35Filgrastim 35Melphalan 33Methotrexate 28Radiotherapy 26Granulocyte Colony-Stimulating Factor 20Sirolimus 17Methylprednisolone 17Etoposide 17Cord Blood Stem Cell Transplantation 17Rituximab 14Stem Cell Transplantation 13Alemtuzumab 13thymoglobulin 11sargramostim 11Cyclosporins 11Therapeutics 10Flow Cytometry 10Cytarabine 10plerixafor 8Thiotepa 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × tinostamustine × Plasma cell × Clear all
NCT02576496 2024-07-25

Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Mundipharma Research Limited

Phase 1 Completed
106 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Multiple Myeloma, Lymphoma, T-Cell, Cutaneous, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡